Chinese biotech Huahui Health has won conditional approval for Libevitug (libevitug) to treat adults with chronic hepatitis D ...

Huahui Health announced that China's National Medical Products Administration (NMPA) has granted conditional approval to its ...

Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its ...

Huahui Health announced that China's National Medical Products Administration (NMPA) has granted conditional approval to its ...

Libevitug works by blocking hepatitis B and D viruses from entering liver cells, targeting the PreS1 domain of the viral ...

Authorities say screening will cover people born in Hong Kong in or before 1988 with family members or sexual partners who ...

Hepatitis C is widely known by name, but far less understood in reality. It's a condition that can exist quietly in the body for years, causing little to no outward sign that anything is wrong, which ...

China's drug regulator has granted conditional approval to Huahui Health's Libevitug injection for the treatment of the chronic hepatitis D virus infection in adults, the company said on Friday.

The deal is the first for new CEO Luke Miels as the British drugmaker looks to overcome pressure on its HIV and vaccines ...

Experts say family support, awareness, expansion of facilities crucial to combat growing menace Srinagar: At a time when drug abuse continues to pose a serious social and public health challenge in ...

GSK plc GSK announced positive results from two phase III studies, B-Well 1 and B-Well 2, which evaluated its investigational chronic hepatitis B (CHB) therapy called bepirovirsen. Both studies met ...